KEE Mapping for Pharma: Identifying Key External Experts Beyond Traditional KOLs
KEE MappingKey External ExpertsBeyond KOLsStrategic Intelligence
A therapy area is shaped by more than its prescribing physicians. Payers decide who can access the therapy. HTA committees decide whether it represents value for money. Patient advocates determine how the patient voice is represented in regulatory and access decisions. Policymakers set the healthcare environment within which all of these decisions are made. KEE mapping identifies all of them — not just the clinical KOLs that traditional mapping programmes cover.
KOL vs KEE: Understanding the Distinction
| Expert Type | KOL? | KEE? | Why They Matter |
|---|---|---|---|
| Academic physicians / clinical researchers | ✓ | ✓ | Shape clinical guidelines, prescribing practice, and trial design |
| Emerging clinical experts | ✓ | ✓ | Future KOLs — the relationships built now last decades |
| Digital opinion leaders (HCPs) | ✓ | ✓ | Shape peer and patient behaviour through digital communities |
| HTA committee members | Rarely | ✓ | Vote on reimbursement recommendations across national markets |
| Health economists | Rarely | ✓ | Design and critique economic models underpinning access submissions |
| Patient advocacy leaders | ✗ | ✓ | Represent patient voice in regulatory and HTA processes; shape public discourse |
| Healthcare policymakers | ✗ | ✓ | Set the regulatory and reimbursement environment all access decisions operate within |
| Digital health innovators | ✗ | ✓ | Driving the transformation of care delivery in ways that affect therapy use and access |
| Academic researchers (adjacent fields) | Sometimes | ✓ | Methodology innovators whose work reshapes how therapies are evaluated |
Who Uses KEE Mapping and Why
🏠 Medical Affairs
Extend scientific exchange planning beyond prescribing physicians to include the researchers, policy advisors, and patient advocates who shape the therapy area’s broader strategic context.
📋 Market Access
Map the HTA experts, health economists, and payer advisors who will evaluate your submission — understanding their positions before you submit, not after.
🌟 Launch Teams
Identify the full range of external voices that will shape launch reception — from prescribing KOLs to the patient advocates and payer influencers who determine whether patients can access the therapy.
🌎 Corporate Affairs
Map the policy landscape — identifying the policymakers, regulators, and thought leaders shaping the healthcare environment your therapies operate in.
How KOL Mapping by VML Approaches KEE Mapping
KOL Mapping by VML’s multi-module framework naturally encompasses KEE identification. The catalyst of change module covers experts and organisations driving policy and practice shifts. The established leader module extends to key academic researchers across relevant disciplines. The DOL module covers digital health policy voices. And the influence mapping module reveals how clinical KOLs, payer experts, and patient advocates interact — showing the network pathways through which scientific and health economic evidence reaches access and policy decisions.
KEE mapping programmes are scoped around the specific functions and strategic objectives that need serving — ensuring the intelligence produced is directly actionable by the teams who commission it.
Frequently Asked Questions
Can KEE mapping cover patient advocacy organisations as well as individual experts?
Yes. KEE mapping can include organisational mapping — identifying the patient advocacy groups, professional associations, and health policy bodies that hold the most strategic influence in a therapy area — alongside individual expert identification. Understanding which organisations hold the most influential positions on specific policy or access questions is as valuable as knowing which individuals do. → Discuss your KEE mapping scope
Is KEE mapping different from stakeholder mapping?
KEE mapping and stakeholder mapping overlap but are not identical. Stakeholder mapping typically covers all parties with an interest in a therapy area or business decision — a broader category that includes healthcare systems, payer organisations, and regulatory bodies as institutions. KEE mapping focuses specifically on the individual external experts whose personal authority, network position, and knowledge give them disproportionate influence on the decisions that matter to a pharma programme. KEE mapping produces actionable engagement intelligence; stakeholder mapping produces an interest landscape.
Map the Full Expert Landscape — Beyond Traditional KOLs
→ Talk to KOL Mapping by VML about KEE mapping for your programme